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Introduction: Exon 19 deletions and the exon 21 L858R
mutation of the epidermal growth factor receptor gene
(EGFR) predict activity of EGFR tyrosine kinase inhibitors,
including erlotinib; however, the ability of less common
EGFR mutations to predict efﬁcacy of erlotinib is unclear.
Methods: The efﬁcacy of erlotinib in individual patients
with rare EGFRmutations from the MERIT, SATURN, TITAN,
TRUST, ATLAS, BeTa, and FASTACT-2 trials was analyzed
and compared with data from the literature.
Results: In the patients tested for biomarkers, the frequency
of rare mutations identiﬁed here ranged from 1.7% (eight of
467) in the SATURN study to 7.4% (27 of 364) in ATLAS. Some
rare mutations were associated with greater clinical beneﬁt
from EGFR tyrosine kinase inhibitor therapy or improved
prognosis independent of treatment,whereas others appeared
to have a poorer prognosis. In particular, exon 18 G719 mu-
tations, exon 19 K757R and E746G mutations, the exon 20
S768I mutation, and the exon 21 G836Smutation appeared to
confer a good outcomewith erlotinib treatment, whereas exon
18 S720I showed a particularly poor outcome. Owing to the
small number of patients with each mutation, however, it is
difﬁcult to conﬁrm whether these rare mutations do indeed
confer sensitivity or resistance to erlotinib.
Conclusions: Erlotinib can have different efﬁcacy
depending on the speciﬁc EGFR mutation. More research isneeded to create a central database such as the My Cancer
Genome database of rare mutations to deﬁnitively conﬁrm
whether these mutations are activating, resistant, or
neutral.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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The epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) erlotinib has been at the forefront
of changes in treatment practice for advanced non–small
cell lung cancer (NSCLC) over the past 10 years. Erlotinib
was initially approved for use in the second- or third-line
setting in an unselected population because of statisti-
cally signiﬁcant improvements in overall survival (OS)
versus placebo.1 Erlotinib was subsequently approved
for maintenance treatment of unselected patients with
NSCLC as a result of data from the SATURN trial.2 Finally,
on the basis of compelling evidence from several clinical
trials of single-agent erlotinib versus chemotherapy,3–5
erlotinib was also approved for the ﬁrst-line treatment
of patients whose tumors harbor activating mutations of
the epidermal growth factor receptor gene (EGFR).
The most common activating mutations used to guide
treatment decisions in NSCLC are deletions in exon 19 of
EGFR and the speciﬁc point mutation L858R in exon 21;
however, many testing methods are actually able to
identify other less common activating mutations, as well
as the most frequent resistance mutations (e.g., T790M
in exon 20). Genetic proﬁling suggests that some patients
with advanced NSCLC whose tumors harbor these less
common mutations of EGFR may derive a greater or
lesser beneﬁt from treatment with erlotinib or other
EGFR TKIs (e.g., afatinib, geﬁtinib) than do those with
classical activating mutations, but full mutation proﬁling
is still in its infancy.
To allow truly personalized treatment, a greater un-
derstanding of these “rare” mutations is required to
facilitate individual patient proﬁling and accurate pre-
diction of response to EGFR TKI therapy. Examining
existing data and tumor samples can provide valuable
guidance in building these disease proﬁles for application
to clinical practice, particularly in cases in which the
number of patients with a speciﬁc mutation is insufﬁcient
to carry out a full clinical trial. De Pas et al. investigated
the frequency of rare mutations in 681 patients with
NSCLC who were screened between 2006 and 2010. Of
the 99 patients with EGFR mutations, 18 harbored rare
mutations. Of these patients, 10 were treated with erlo-
tinib or geﬁtinib, with varying responses depending on
the speciﬁc mutations.6 In an observational, prospective
cohort of 188 NSCLC patients, common and rare muta-
tions were assessed with regard to EGFR TKI response by
Arrieta et al. Patients with rare mutations had signiﬁ-
cantly (p < 0.001) lower response rates to EGFR TKIs
than did those with common mutations.7 Similarly, Chiu
et al.8 examined 639 patients with activating EGFR mu-
tations (478 with common mutations and 161 with rare
mutations). When patients were treated with EFGR TKIs,
the response rate was signiﬁcantly lower for those withrare mutations than for those with common mutations
(41.6% versus 66.5%, p ¼ 0.001) and the median
progression-free survival (PFS) was also lower (7.7
versus 11.4 months, p¼ 0.001).8 A retrospective analysis
by Baek et al. also reported that patients with rare or
complex mutations had inferior response and survival
when treated with EGFR TKIs compared with patients
whose tumors had common EGFR mutations.9
In a post hoc analysis from three clinical studies of
afatinib (LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6), 75 of
600 patients (12%) had rare EGFR mutations, and after
afatinib treatment, themedianPFS varieddepending on the
type of mutation.10 Patients with point mutations or du-
plications had a median PFS of 10.7 months and a median
OS of 19.4 months, whereas patients with de novo T790M
mutations had amedianPFSof 2.9months and amedianOS
of 14.9 months. Patients with an exon 20 insertion had a
median PFS of 2.7 months and median OS of 9.2 months.10
Here we use a case report style to report individual
patient data from patients with rare mutations as
assessed from baseline tumor samples in several well-
controlled clinical studies of erlotinib to assess the efﬁ-
cacy outcomes for patients with uncommon mutations.Methods
Clinical Studies Included in This Analysis
Data from the SATURN (NCT00556712), TITAN
(NCT00556322), TRUST (NCT00949910), ATLAS
(NCT00257608), BeTa (NCT00130728), FASTACT-2
(NCT00883779), and MERIT (BO18279) studies were
assessed in this analysis. MERIT was a single-arm, open-
label, phase II gene expression proﬁling study that aimed
to identify candidate genes in order to predict outcomes
in patients receiving erlotinib.11 The TRUST study was a
phase IV expanded access study that assessed efﬁcacy
and safety outcomes with erlotinib (regardless of line of
therapy) in a large patient population reﬂective of real-
life clinical practice (>7000 patients).12 Biomarker
samples were obtained where possible and several prior
analyses were carried out, including analyses of EGFR
mutations.13,14 SATURN and TITAN were twin phase III
studies conducted in the post–ﬁrst-line setting. Patients
were initially enrolled into a chemotherapy run-in phase,
after which they could be enrolled into either SATURN
(if their disease had not yet progressed) or TITAN (if their
disease had progressed during the initial cycles of ﬁrst-
line chemotherapy). Patients in SATURN were random-
ized to receive either erlotinib maintenance therapy or
placebo,2 whereas those in TITAN were randomized to
receive either second-line erlotinib or chemotherapy
(docetaxel or pemetrexed, at the investigators’ dis-
cretion).15 Tumor sampling was mandatory in both
April 2016 Erlotinib with NSCLC and Rare EGFR Mutations 547studies, and extensive biomarker analyses have been
reported.15,16 FASTACT-2 was a phase III, randomized,
controlled study assessing the efﬁcacy and safety of an
intercalated regimen of erlotinib and ﬁrst-line chemo-
therapy versus intercalated placebo and chemotherapy in
Asian patients with advanced NSCLC. Patients were not
selected on the basis of EGFR mutation status, but bio-
marker analysis did demonstrate that the signiﬁcant ef-
ﬁcacy beneﬁt of intercalated erlotinib was driven by this
patient subgroup.17 BeTa was a phase III randomized
study evaluating bevacizumab plus erlotinib for the
treatment of recurrent or refractory NSCLC. Patients
were not selected on the basis of EGFR mutation status,
but tumor biopsy material was requested at study entry
for biomarker analysis.18 The phase III ATLAS study
assessed bevacizumab with or without erlotinib in the
maintenance treatment setting.19 Provision of tumor tis-
sue for biomarker assessment was optional.
Mutation Testing Methodology
Tumor sampling was mandatory for MERIT, SATURN,
and TITAN, and optional for TRUST, ATLAS, BeTa, and
FASTACT-2; informed consent was obtained from all
patients contributing samples. EGFR mutation testing
was carried out using different methods across the
different clinical studies. For MERIT and TRUST,
microdissection (manual or laser capture) of tumor cells
was carried out on formalin-ﬁxed parafﬁn-embedded
tissue samples. DNA was then extracted from the
microdissected cells, and EGFR exons 18 through 21
were ampliﬁed by polymerase chain reaction (PCR) and
then sequenced for EGFR mutation status assessment. In
SATURN and TITAN, DNA lysates were obtained from
macrodissected or microdissected tissue samples; these
samples had to have at least 5000 tumor cells and a
minimum 60% tumor cell content. Exons 18 through 21
were ampliﬁed by PCR, with multiple independent
products sequenced. Mutations other than the most
commonly known resistance and activating mutations
had to be identiﬁed in at least two PCR products to be
conﬁrmed. For FASTACT-2, EGFR mutation analysis was
carried out using the cobas 4800 system (Roche Mo-
lecular Diagnostics, Pleasanton, CA), which is able to
detect the most common activating and resistance mu-
tations, as well as less common mutations in exons 18
through 21. In addition, blood samples were tested us-
ing the cobas 4800 EGFR mutation blood test (in
development). In the ATLAS study, analyses of EGFR
mutations in exons 18 through 21 were performed with
Somatic Mutation Scanning by Surveyor Endonuclease
Digestion and Analysis on WAVE HS (Transgenomics
Inc., Omaha, NE) using cells captured by manual mac-
rodissection or laser microdissection. In the BeTa study,
EGFR mutations in exons 18 through 21 were analyzedby denaturing high-performance liquid chromatography
(Transgenomics Inc.).
Results
To effectively assess the efﬁcacy of erlotinib in pa-
tients with the rare mutations identiﬁed, it is important
to consider the results for the intent-to-treat population
and, where available, the results for subgroups with
classical EGFR mutations from each study shown in
Supplementary Table 1.
Individual Patient Data for Rare Mutations
Efﬁcacy results for individual patients with rare mu-
tations in MERIT, SATURN, TITAN, TRUST, ATLAS, BeTa,
and FASTACT-2 are presented in Tables 1 through 4
(Table 1, rare mutations in exon 18; Table 2, rare mu-
tations in exon 19; Table 3, rare mutations in exon 20;
and Table 4, rare mutations in exon 21). In the samples
tested for biomarkers, the frequency of rare mutations
identiﬁed in this analysis ranged from 1.7% (eight of
467) in the SATURN study to 7.4% (27 of 364) in ATLAS.
Some mutations were associated with greater clinical
beneﬁt from EGFR TKI therapy or with improved prog-
nosis regardless of treatment, showing both predictive
and prognostic effects of certain rare mutations, whereas
others appeared to have a detrimental effect on survival.
Some of these rare mutations are detailed in the
following sections, evaluating the results from this
analysis in comparison with data from the literature.
Exon 18 Mutations
G719. One of the more frequently observed “rare” mu-
tations is the point mutation at G719 (n ¼ 10 of 24 exon
18 mutations in this analysis). The mutation to cysteine
(G719C) appears to confer a PFS and OS beneﬁt, with
one patient from the SATURN study reporting a partial
response, PFS of 500 days, and OS of 795 days (>2
years). When this mutation was combined with the
K714N mutation in one patient in BeTa, an OS of 973
days (>2.5 years) was observed. A point mutation to
alanine was also seen at G719. In SATURN, a G719A
mutation plus T725M resulted in a PFS of 169 days and
OS of 343 days, whereas in TRUST, a patient with G719A
had a PFS of 463 days and OS of 488 days. A patient in
FASTACT-2 with an unknown G719 mutation achieved
an OS of 1008 days (>2.5 years). When compared with
the PFS and OS results from the overall populations of
each study, the G719A mutation appeared to be sensi-
tizing, but to a lesser extent than the G719C mutation.
Literature Review. Substitutions at G719 with alanine or
cysteine have been shown to confer sensitivity to EGFR
TKIs in several previous studies. This is because the point
Table 1. Efﬁcacy Data for Rare Mutations in Exon 18 of EGFR
Protocol Age, y Sex Race ECOG PS
Tx
Line
Smoking
Status First Trial Medication
Actual Mutation
Exon 18 Response PFS, d OS, d D or C
TITAN 64 Male White 0 2 Current Docetaxel P.G719Aa PD 25 25 C
SATURN 58 Male White 1 1 Former Erlotinib P.E709A; P.G719S SD 253 509 C
SATURN 58 Female Asian 1 1 Never Erlotinib P.G719C PR 500 795 C
SATURN 59 Male White 0 1 Current Erlotinib P.G719A; P.T725M SD 169 343 D
MERIT 50 Male Asian 1 2 Never Erlotinib P.E709K; P.G719A PD 42 259 D
TRUST 67 Female White 1 2 Never Erlotinib P.G719Ab SD 463 488 D
TRUST 50 Female Asian 1 2 Never Erlotinib P.E709_T710DELINSD PD 38 52 D
TRUST 38 Male Asian 2 2 Never Erlotinib P.V689Mb SD 491 873 D
FASTACT-2 61 Female Asian 0 1 Never Carboplatin/gemcitabine P.G719UNKc SD 225 1084 D
FASTACT-2 63 Female Asian 1 1 Never Carboplatin/gemcitabine P.G719UNKd PR 130 1008 D
ATLAS 72 Male White 1 1 Former Bevacizumab þ erlotinib P.L707Se PD 42 235 C
ATLAS 41 Male White 1 1 Current Bevacizumab þ erlotinib P.I715V SD 413 413 C
ATLAS 73 Male White 1 1 Former Bevacizumab þ erlotinib P.S720P PD 78 285 C
ATLAS 67 Female Black 1 1 Former Bevacizumab þ erlotinib T727STOP PD 1 464 D
ATLAS 61 Male White 1 1 Current Bevacizumab þ erlotinib P.S720P SD 109 302 C
ATLAS 64 Male White 1 1 Current Bevacizumab þ erlotinib P.F723L PD 81 311 C
ATLAS 73 Female Hispanic 1 1 Current Bevacizumab P.G719C SD 453 673 D
ATLAS 70 Male Hispanic 0 1 Former Bevacizumab P.G719A PD 84 227 C
ATLAS 59 Male White 1 1 Former Bevacizumab þ erlotinib P.S720F PD 2 89 C
ATLAS 70 Male Asian 1 1 Former Bevacizumab þ erlotinib P.V736A NE 177 183 D
BeTa 77 Female White 1 2/3 Former Erlotinib þ placebo P.K714N; P.G719C SD 359 973 C
BeTa 74 Female White 0 2/3 Former Erlotinib þ placebo P.Y727C SD 191 269 D
BeTa 64 Female White 0 2/3 Former Erlotinib þ bevacizumab P.I706T; P.G874S SD 423 444 C
BeTa 61 Female White 0 2/3 Former Erlotinib þ placebo P.A722Vf PD 39 429 C
aExon 21 L833F mutation in addition.
bExon 20 mutation in addition.
cPatient received second-line erlotinib.
dPatient received second-line geﬁtinib.
eExon 19 N7565 mutation in addition.
fExon 19 deletion in addition.
C, censored; D, death; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor gene; NE, nonevaluable; OS, overall survival; PFS, progression-free survival; PR,
partial response; PD, progressive disease; SD, stable disease; Tx, treatment.
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April 2016 Erlotinib with NSCLC and Rare EGFR Mutations 549mutation alters the P-loop of the receptor structure to
allow the receptor a higher afﬁnity to adenosine triphos-
phate (ATP), therefore favoring activation.20 Han et al.9
reported three geﬁtinib-treated patients with G719A
mutations. Of these patients, two achieved partial re-
sponses, with one patient reporting a time to progression
of 22 months (z669 days) and an OS longer than 26
months (z791 days).21 Point mutations at G719 resulted
in 15 patients achieving a response rate of 53.3%, median
PFS of 8.1 months (z247 days), and median OS of 16.4
months (z499 days) when treated with geﬁtinib or
erlotinib.22 Baek et al. reported that in a subgroup in
which six of 11 patients had G719 mutations, median PFS
was 5.1 months (z155 days) and median OS was 18.3
months (z557 days) in a retrospective analysis.9 When
patients with point mutations at G719 (n ¼ 18) were
treated with afatinib, they achieved an objective response
rate (ORR) of 77.8%, PFS of 13.8 months, and OS of 26.9
months in a study by Yang et al.10 Chui et al. reported
that 78 of 161 (48.4%) patients with rare mutations had
a single G719 mutation. After treatment with geﬁtinib
or erlotinib, the ORR was 36.8% with a disease control
rate (DCR) of 72.4%. However, a compound mutation of
G719 þ L861Q (exon 21) (5.6%) or G719 þ S768I (exon
20) (6.2%) demonstrated a higher ORR (88.9% and 50%,
respectively) and a greater DCR (100% for both).8
S720. Poor response and short OS were observed with
the S720P mutation, with an OS less than 1 year seen in
two patients from the ATLAS study (285 and 302 days).
One patient from ATLAS with a S720F mutation had an
OS of 89 days, suggesting that this mutation may be
associated with particularly poor survival outcomes;
however, a larger sample size would be needed to
conﬁrm such an association as this result could be due to
comorbidities or certain other patient characteristics.
Literature Review. Very little has been published re-
garding mutations at S720. In a study of mutation type in
patients treated with geﬁtinib, however, a female Asian
nonsmoker with the S720P mutation had a median PFS of
13.2 months (z402 days) and median OS of 20.5 months
(z624 days).23 This suggests that tumors with the same
mutation may react differently to different TKIs; how-
ever, the small sample size limits interpretation.Exon 19 Mutations
Response and survival varied considerably between
the different rare exon 19 mutations. Mutations that
appeared sensitizing to EGFR TKIs were K757R (n ¼ 1)
and E746G (n ¼ 1), which resulted in a PFS of 250 and
415 days in MERIT and BeTa, respectively, and an OS of
more than 1 year (435 days in MERIT and 462 days in
Table 3. Efﬁcacy Data for Rare Mutations in Exon 20 of EGFR
Protocol Age, y Sex Race ECOG PS
Tx
Line
Smoking
Status First Trial Medication
Actual Mutation
Exon 20 Response PFS, d OS, d D or C
TITAN 54 Male Asian 1 2 Current Docetaxel P.A767_S768INSSVSS PD 17 64 D
TITAN 56 Male Asian 1 2 Never Docetaxel P.M766_A767INSASV SD 81 115 D
SATURN 64 Female White 1 1 Former Erlotinib P.T790M PD 47 134 C
SATURN 53 Female White 1 1 Never Erlotinib P.D770_N771INSSVD SD 84 599 C
SATURN 51 Female White 1 1 Never Erlotinib P.D770_N771INSSVD PR 128 881 C
TRUST 67 Male White 2 2 Never Erlotinib P.ALA767_VAL769DUP SD 71 155 D
TRUST 60 Male White 2 2 Never Erlotinib P.A763_Y764INSFQEA PR 532 731 D
TRUST 67 Female White 1 2 Never Erlotinib P.T790Ma SD 463 488 D
TRUST 70 Male White 1 2 Never Erlotinib P.H773_V774INSAH PD 53 390 D
TRUST 62 Female Asian 1 2 Never Erlotinib P.S768I; P.V774M SD 166 1106 C
TRUST 85 Female White 1 2 Never Erlotinib P.V769_D770INSASV NE 642 642 D
TRUST 38 Male Asian 2 2 Never Erlotinib P.T790Ma SD 491 873 D
FASTACT-2 61 Female Asian 0 1 Never Carboplatin/gemcitabine P.S768Ia SD 225 1084b D
FASTACT-2 62 Male Asian 0 1 Never Carboplatin/gemcitabine þ erlotinib P.S768I PR 371 1909b C
FASTACT-2 56 Female Asian 1 1 Never Carboplatin/gemcitabine P.S768I SD 169 939 D
ATLAS 57 Male White 1 1 Former Bevacizumab P.A763Vb CR 689 827 D
ATLAS 71 Male White 1 1 Former Bevacizumab þ erlotinib P.P772S NE 75 75 C
ATLAS 33 Female Black 1 1 Never Bevacizumab þ erlotinib P.D746Ab PR 424 435 D
ATLAS 58 Male Asian 1 1 Current Bevacizumab þ erlotinib P.V774M PD 36 82 C
BeTa 61 Male White 1 2/3 Former Erlotinib þ bevacizumab P.K860E PD 39 127 D
BeTa 67 Female White 1 2/3 Never Erlotinib þ placebo INS PD 42 354 D
BeTa 70 Male White 1 2/3 Former Erlotinib þ placebo T790M PR 296 498 D
BeTa 69 Male White 0 2/3 Never Erlotinib þ placebo T790Mc PD 40 665 C
BeTa 60 Female White 1 2/3 Former Erlotinib þ placebo T790Mb NE 27 27 D
BeTa 50 Female White 1 2/3 Former Erlotinib þ bevacizumab S768I; V769L PR 83 125 D
aExon 18 mutation in addition.
bExon 19 deletion in addition.
cExon 21 mutation in addition.
C, censored; CR, complete response; D, death; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor gene; NE, nonevaluable; OS, overall survival; PFS,
progression-free survival; PR, partial response; PD, progressive disease; SD, stable disease; Tx, treatment.
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Table 4. Efﬁcacy Data for Rare Mutations in Exon 21 of EGFR
Protocol Age, y Sex Race ECOG PS
Tx
Line
Smoking
Status First Trial Medication
Actual Mutation
Exon 21 Response PFS, d OS, d D or C
TITAN 60 Male Asian 1 2 Never Erlotinib P.L861Q PD 18 18 D
TITAN 51 Male White 1 2 Current Pemetrexed P.P848L PD 50 173 D
TITAN 64 Male White 0 2 Current Docetaxel P.L833Fa PD 25 25 C
SATURN 47 Female White 0 1 Current Erlotinib P.P848L SD 78 655 C
SATURN 63 Male White 0 1 Former Placebo P.H835L; P.L833V SD 85 308 D
TRUST 42 Female White 2 2 Current Erlotinib P.D837N SD 52 52 D
TRUST 56 Male White 2 2 Current Erlotinib P.K860N SD 354 354 D
FASTACT-2 48 Female Asian 1 1 Never Carboplatin/gemcitabine P.L861Q PR 141 175 D
ATLAS 63 Female White 1 1 Former Bevacizumab P.L858Q; P.V834A PD 36 137 C
ATLAS 62 Female White 1 1 Current Bevacizumab þ erlotinib P.R841G; P.A859V PD 39 52 C
ATLAS 78 Male White 1 1 Former Bevacizumab þ erlotinib P.H870Y SD 85 691 D
ATLAS 52 Female White 1 1 Current Bevacizumab þ erlotinib P.L858Rb SD 126 728 D
ATLAS 53 Female White 0 1 Former Bevacizumab þ erlotinib P.L858R; L861P PD 212 348 C
ATLAS 69 Female White 1 1 Former Bevacizumab þ erlotinib P.A840V; P.A859T PR 85 407 C
ATLAS 23 Male White 0 1 Never Bevacizumab P.G836S PD 46 763 D
ATLAS 72 Female White 1 1 Current Bevacizumab þ erlotinib P.G836S PR 429 642 D
ATLAS 88 Male White 0 1 Former Bevacizumab þ erlotinib P.A871V SD 125 313 D
ATLAS 43 Female White 1 1 Former Bevacizumab P.V843Ib SD 127 511 D
ATLAS 70 Male White 1 1 Former Bevacizumab P.Q849S NE 78 184 C
ATLAS 71 Female Black 0 1 Current Bevacizumab P.G824D; P.V851A PD 78 293 C
BeTa 58 Male White 1 2/3 Former Erlotinib þ bevacizumab Y827C; V845M; H870Yc NE 85 282 D
BeTa 61 Female Hispanic 1 2/3 Never Erlotinib þ placebo P.H835R PR 417 460 C
BeTa 69 Male White 0 2/3 Never Erlotinib þ placebo P.L858Rb PD 40 665 C
BeTa 69 Male White 1 2/3 Current Erlotinib þ placebo P.R831C; P.T854Id SD 116 116 D
BeTa 64 Female White 0 2/3 Former Erlotinib þ bevacizumab P.G874Se SD 423 444 C
BeTa 72 Male White 1 2/3 Former Erlotinib þ bevacizumab P.L861Q SD 234 339 C
BeTa 47 Female Black 1 2/3 Former Erlotinib þ placebo P.T854I PD 39 104 D
BeTa 67 Female White 1 2/3 Former Erlotinib þ placebo P.V851Af SD 215 329 C
BeTa 64 Female White 0 2/3 Former Erlotinib þ bevacizumab P.L838V; P.L858R SD 211 430 C
BeTa 78 Female White 0 2/3 Former Erlotinib þ bevacizumab P.A859T NE 36 687 C
BeTa 53 Female White 0 2/3 Former Erlotinib þ bevacizumab P.D855V SD 173 259 C
aExon 18 mutation in addition.
bExon 20 T790M mutation in addition.
cExon 19 K745E in addition.
dExon 19 deletion in addition.
eExon 18 I706T mutation in addition.
fExon 19 A755T mutation in addition.
C, censored; D, death; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor gene; NE, nonevaluable; OS, overall survival; PFS, progression-free survival; PR,
partial response; PD, progressive disease; SD, stable disease; Tx, treatment.
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PFS and OS than the previously mentioned mutations,
with a best response of progression or stable disease.
However, these results were comparable with the results
for the overall study population, so EGFR TKI treatment
is unlikely to be of reduced beneﬁt in these patients.
Literature Review. To our knowledge, no previous
publications have reported K757R mutations. The E746G
mutation was reported in combination with an L861Q
mutation in a study by Wu et al., with the patient
achieving a partial response to EGFR TKI therapy.22 A
study by Peng et al.24 reported deletions at E746 in two
patients who both received geﬁtinib treatment. One pa-
tient had a stable disease status, a PFS of 8 months, and
an OS of more than 8 months, and the other patient
achieved a partial response, a PFS of 15 months, and an
OS of more than 58 months.24 Exon 19 insertions, L747F
and P733L, have both been reported as sensitizing rare
exon 19 mutations20 and several rare mutations in exon
19 have been reported as resistance mutations, including
D761Y, E746V, and L747S, showing the varied responses
that different point mutations in one exon can elicit.20
The L747F mutation may confer sensitivity by inhibit-
ing the aC helix adopting the inactive position,25 whereas
the D761Y resistance mutation appears to confer resis-
tance by altering the receptor interaction with ATP.20 In
two case studies by Agbarya et al. and Chan et al., data
from female patients with p.K745_E746insIPVAIK exon
19 insertions were reported, and in both cases the pa-
tients responded to EGFR TKI treatment.26,27Exon 20 Mutations
T790M is known to cause EGFR TKI resistance,28
which is generally consistent with the short PFS seen
in patients with this mutation in our analysis. When
combined with exon 18 mutations, however, a response
of stable disease and a PFS of more than 1 year was seen
in two patients from the TRUST study. In the case of
double mutations, however, the mutant allele frequency
must be considered because if the mutant allele fre-
quency for T790M were to be particularly low when in
combination with another mutation, the outcome would
be skewed toward the other mutation, although the
presence of the T790M resistance mutation would still
be detected. S768I appeared to confer sensitivity to
erlotinib, with a patient from FASTACT-2 reaching an OS
of 1909 days (>5 years) and a female Asian patient from
the TRUST study with an additional V774M mutation
having an OS of 1106 days (>3 years). Across the exon
20 mutations reported, eight appeared to be insertions.
P.A767_S768INSSVSS and P.M766_A767INSASV from the
TITAN study were associated with short PFS and OS.Conversely, the P.D770_N771INSSVD mutation was
associated with longer OS (599 and 881 days) in two
patients in the SATURN study.Literature Review. Masago et al. published a case report
of a patient with an S768I mutation who had achieved a
partial response and PFS of more than 1 year while
receiving second-line geﬁtinib treatment.29 Other reports
have identiﬁed the S768I mutation as a resistance mu-
tation22,30 or as a mutation less sensitive to erlotinib or
geﬁtinib than to dual EGFR and the vascular EGFR in-
hibitor AEE788.31 Chiu et al. reported seven patients with
the S768I mutation who achieved an ORR of 33.3% and
DCR of 66.7%, although patients with a compound S768
mutation (n ¼ 10) showed a PFS of 11.9 months
compared with 6.5 months for the single mutation.8 A
study in Norway identiﬁed three patients with S768I
mutations, two of whom went on to receive EGFR TKI
treatment. One patient had a partial response to ﬁrst-line
geﬁtinib, with a treatment time of 14months, whereas the
other patient received second-line erlotinib for 1 month
until disease progression.32 The conﬂicting reports
highlight how difﬁcult it can be to obtain a consensus on
whether a mutation is resistant, activating, or neutral
when so few cases are reported. Exon 20 mutations may
function by altering the kinase domain conformation.20
Although many exon 20 mutations have been reported
as conferring resistance to erlotinib by altering the P-loop
and thus reducing the ATP-binding pocket,25 a retrospec-
tive study by Naidoo et al. reported a V769_770insASV
insertion that resulted in a PFS of 19.8 months (z602
days) and an OS of 24 months (z730 days), and a patient
with a D770_N771insGT insertion achieving an OS of 55
months (z1674 days), thus demonstrating the variability
of rare mutation effects.33 Another retrospective study
analyzed 1086 patients for EGFRmutations and identiﬁed
27 patients (2.5%) with exon 20 insertions, with the most
common variant being V769_D770insASV.34 In this study,
exon 20 insertions were associated with a median PFS of
16 months and were more commonly found in never-
smokers and Asian patients.34Exon 21 Mutations
Response varied among the speciﬁc exon 21 muta-
tions. Generally rare mutations in exon 21 resulted in a
PFS of less than 6 months (182 days) and an OS of less
than 1 year, with disease progression or stable disease
reported as the best response. However, P848L, H870Y,
G836S, and L858R þ T790M mutations all resulted in an
OS of longer than 1.5 years (547 days), with the G836S
mutation also providing a PFS of longer than 1 year
(>365 days) and partial response observed as the best
overall response. The patient with the H870Y mutation
April 2016 Erlotinib with NSCLC and Rare EGFR Mutations 553(OS 691 days) and another patient with a G836S muta-
tion (OS 763 days) both continued to receive erlotinib
treatment after progression, which could be linked to
their longer OS.Literature Review. As with our analysis, many rare
mutations in exon 21 have been identiﬁed with varying
responses.20 The L861Q mutation has been investigated
extensively and is reported to be a sensitizing mutation
that increases kinase activity, whereas L861R and L862V
have been reported as resistance mutations.6 In the
NEJ002 study, OS was signiﬁcantly lower for patients
with rare mutations (G719X or L861Q) than for those
with common EGFR mutations (p ¼ 0.002). Patients with
rare EGFR mutations (G719X or L861Q) treated with
geﬁtinib had a signiﬁcantly shorter OS (11.9 versus 29.3
months; p < 0.001). Interestingly, OS was similar be-
tween patients with uncommon and common mutations
when treated with carboplatin-paclitaxel (p ¼ 0.358).35
Discussion
Although the classical EGFR activating mutations of
exon 19 deletions and exon 21 L858R mutations have
been proved to act as sensitizing mutations for erlotinib,
how other less common EGFR mutations affect erlotinib
efﬁcacy is unclear. These analyses demonstrate the
considerable variation in treatment outcome for patients
whose tumors harbor different uncommon EGFR muta-
tions. Although the general consensus in the literature is
that rare mutations are associated with inferior re-
sponses to TKI therapy, our analyses showed that many
rare mutations result in efﬁcacy similar to that seen in
unselected populations or patients with classical acti-
vating mutations; therefore, patients with these muta-
tions should not necessarily be excluded from receiving
EGFR TKI therapy. Some rare mutations might even slow
tumor growth or metastasis compared with wild-type
disease, and patients with these mutations might sur-
vive longer even without treatment. Also, some patients
with rare mutations had a particularly positive outcome
with erlotinib treatment, which may help to identify
those uncommon mutations that are potentially predic-
tive of an efﬁcacy beneﬁt with this therapy.
Our analysis reported that exon 18 G719 mutations,
exon 19 K757R and E746G mutations, the exon 20 S768I
mutation, and the exon 21 G836S mutation appeared to
confer a good outcome with erlotinib treatment, whereas
exon 18 S720I showed a particularly poor outcome.
Because of the small number of patients with each mu-
tation, however, it is difﬁcult to conﬁrm whether these
rare mutations do indeed confer sensitivity or resistance
to erlotinib. Our results are similar to those of the afa-
tinib analysis of uncommon EGFR mutations, whichobserved tumor responsiveness and prolonged PFS in
afatinib-treated patients with G719X mutations and
L858R þ T790M mutation; however, in contrast to our
ﬁndings, S786I and S786I þ L858R mutations were
thought to be sensitizing in the afatinib study.10 In a
retrospective study by Naidoo et al., the exon 20
D770_N7719nsSVD mutation had low OS (3 months
[z91 days] and 10 months [z302 days])33; in this
analysis, however, these mutations appeared to confer
long OS (599 days and 881 days in two patients in
SATURN). This variation between analyses could be due
to the mutations having a different effect with different
TKIs, or it could simply highlight the difﬁculty in con-
ﬁrming a class effect with so few cases.
The difﬁculty in testing the efﬁcacy of targeted agents
against speciﬁc mutations is that because they occur at
extremely rare frequencies, it is practically impossible to
enroll enough patients to power a clinical trial except by
using large-scale screening and complicated treatment
allocation algorithms. This means that analyses of rare
mutations are unlikely to reach statistical signiﬁcance.
Even if the same mutation is seen across several studies,
the difference in study design, end points, and agents
investigated means that it is hard to reliably pool data to
gain a consensus on mutation type. Despite these issues
in reliability of analysis, rare mutations are important to
consider because licensed indications are usually speciﬁc
to certain common mutations and those who might
beneﬁt considerably from a speciﬁc targeted therapy
could be missing out on effective treatment with the
current approach. This can be seen by comparing the U.S.
labels for ﬁrst-line erlotinib and afatinib, on which the
indications are speciﬁed as exon 19 deletions and exon
21 L858R, with the EU labels, which mention only EGFR
activating mutations (therefore, rare mutations could be
included).
One potential limitation of the current diagnostic
approach of testing only for common exon 19 and 21
mutations, as was done in the EURTAC or OPTIMAL
studies,4,5 is that such an approach might miss identifying
a number of patients who could have some beneﬁt from
EGFR TKI treatment. Additional evidence may be needed
to support conclusions regarding the predictive value of
speciﬁc mutations that are less commonly observed.
Another consideration limiting the current approach is
that the mutation proﬁle of a patient’s tumor may change
throughout the course of disease. As the difference be-
tween activating, neutral, and resistance mutations can
make a sizable difference in how a patient’s disease
responds to EGFR TKI therapy, it is important to identify
as many of these mutations as possible to guide treat-
ment, however infrequent particular mutations are.
Some researchers have taken the reverse app-
roach to that taken in this analysis and have identiﬁed
554 Klughammer et al Journal of Thoracic Oncology Vol. 11 No. 4patients with exceptional responses to speciﬁc thera-
pies, and then carried out full gene analysis on patients’
tumor tissue to identify which mutation may be driving
that response.36 The limitation of this approach is that
it can be a time-consuming process and would rely on
patients being given off-label experimental treatments
to assess whether their tumors respond, which is not
an option for many clinicians owing to strict formu-
laries and reimbursement issues. Online registries of
oncogenic mutations, such as MyCancerGenome,37 may
act as a central repository of observed outcomes with
different treatments in different tumors, but this in-
formation is still incomplete and will require further
research and knowledge sharing by all cancer re-
searchers and clinicians to become a feasible clinical
resource.
The use of more sensitive testing techniques such as
next-generation sequencing and the potential use of
blood samples to make it simpler to obtain material for
testing may in the future make it more feasible to assess
both rare mutations and the classical mutations already
used for diagnosis. This would be helpful to get a more
accurate picture of mutation status for patient selection
for upfront TKI treatment.
Conclusions
Further research is clearly needed to better under-
stand the impact of rare mutations in EGFR and other
genes involved in lung cancer tumorigenesis. As these
mutations are increasingly being detected by standard
testing methods, it is important to have a central re-
pository of information about the implications of speciﬁc
mutations for patient prognosis and treatment choice.
Large-scale investigation in clinical trials is unlikely to be
an option in evaluating treatments in these very small
patient subgroups, so clinicians will need to be proactive
in ﬁnding other methods to determine optimal therapy
choice.
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